

1 **Airway antibodies wane rapidly after COVID-19**
2 **but B cell memory is generated across disease severity**

3
4 Alberto Cagigi¹, Meng Yu¹, Sara Falck-Jones¹, Sindhu Vangeti¹, Björn Österberg¹, Eric
5 Åhlberg¹, Lida Azizmohammadi¹, Ryan Falck-Jones^{2,3}, Pia C Gubisch¹, Mert Ödemis¹,
6 Farangies Ghafoor¹, Klara Lenart¹, Max Bell^{2,3}, Niclas Johansson^{4,5}, Jan Albert^{6,7}, Jörgen
7 Sälde⁸, Deleah Pettie^{9,10}, Michael Murphy^{9,10}, Lauren Carter^{9,10}, Neil P King^{9,10}, Sebastian Ols¹,
8 Anna Färnert^{4,5}, Karin Loré^{1*} and Anna Smed-Sörensen^{1*}
9

10 ¹Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet,
11 Karolinska University Hospital, Stockholm, Sweden. ²Department of Physiology and
12 Pharmacology, Karolinska Institutet, Stockholm, Sweden. ³Department of Perioperative
13 Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden. ⁴Division of
14 Infectious Diseases, Department of Medicine Solna, Center for Molecular Medicine,
15 Karolinska Institutet, Sweden. ⁵Department of Infectious Diseases, Karolinska University
16 Hospital Solna, Stockholm, Sweden. ⁶Department of Microbiology, Tumor and Cell Biology,
17 Karolinska Institutet, Stockholm, Sweden. ⁷Clinical Microbiology, Karolinska University
18 Hospital Solna, Stockholm, Sweden. ⁸Närakut SLSO, Karolinska University Hospital Solna,
19 Stockholm, Sweden. ⁹Department of Biochemistry, University of Washington, Seattle, WA
20 98195, United States. ¹⁰Institute for Protein Design, University of Washington, Seattle, WA
21 98195, United States.
22

23 Karin Lore´ and Anna Smed-Sörensen contributed equally to this study.
24

25 ***Corresponding authors:**

26 Karin Loré and Anna Smed-Sörensen, Division of Immunology and Allergy, Department of
27 Medicine Solna, Karolinska Institutet, Visionsgatan 4, BioClinicum J7:30, Karolinska
28 University Hospital, 171 64 Stockholm, Sweden.
29 e-mail addresses: karin.lore@ki.se; anna.smed.sorensen@ki.se
30
31

32 **Introductory paragraph:**
33

34 Understanding immune responses following SARS-CoV-2 infection in relation to COVID-19
35 severity is critical to predicting the effects of long-term immunological memory on viral
36 spread. Here we longitudinally assessed systemic and airway immune responses against
37 SARS-CoV-2 in a well-characterized cohort of 147 infected individuals representing the full
38 spectrum of COVID-19 severity; from asymptomatic infection to fatal disease. High systemic
39 and airway antibody responses were elicited in patients with moderate to severe disease,
40 and while systemic IgG levels were maintained after acute disease, airway IgG and IgA
41 declined significantly. In contrast, individuals with mild symptoms showed significantly lower
42 antibody responses but their levels of antigen-specific memory B cells were comparable with
43 those observed in patients with moderate to severe disease. This suggests that antibodies in
44 the airways may not be maintained at levels that prevent local virus entry upon re-exposure
45 and therefore protection via activation of the memory B cell pool is critical.
46

47 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

48 **Main:**

49

50 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes
51 coronavirus disease 2019 (COVID-19) can present with a wide range of disease severity from
52 asymptomatic to fatal. Individuals of advanced age and/or those with comorbidities are
53 overrepresented among those who develop severe disease¹. However, the majority of SARS-
54 CoV-2 infected individuals experience asymptomatic infection or only mild disease².

55 Whether patients with different disease severities generate similar protective immunity is
56 still unknown. Here we present data generated from a clinically well-characterized cohort of
57 individuals with SARS-CoV-2 infection (n=147) representing the full spectrum of COVID-19
58 severity ranging from asymptomatic infection to fatal disease. Individuals were sampled
59 during acute disease and convalescence with longitudinal, matched blood and airway
60 samples. The levels of systemic and airway antibody responses as well as the generation of
61 SARS-CoV-2-specific memory B cells were measured. Plasma, peripheral blood mononuclear
62 cells (PBMC), nostril swabs (NSW) and nasopharyngeal aspirates (NPA) were collected across
63 all disease severities whereas endotracheal aspirates (ETA) were collected only from
64 intubated patients receiving intensive care (Figure 1a). Disease severity was assessed on a
65 seven-point scale derived from the respiratory domain of the sequential organ failure
66 assessment (SOFA) score^{3,4}, with additional levels for non-admitted mild cases (1) and fatal
67 cases (7). Patients were grouped based on peak disease severity (PDS) (Supplementary table
68 1 and online methods). In addition, pre-pandemic healthy controls (PPHC) (n=30) as well as
69 individuals who experienced influenza-like symptoms and were possibly exposed to SARS-
70 Cov-2 but had a negative diagnostic PCR (PCR-) (n=9) were sampled in the same way and
71 included as controls (Supplementary table 2 and online methods).

72

73 We first assessed systemic IgG and IgA responses at the time of study inclusion that ranged
74 between 0-54 days from onset of symptoms; median 16 days, and at the first follow-up visit
75 during convalescence (46-168 days; median 108 days). Plasma IgG and IgA against the SARS-
76 CoV-2 nucleocapsid (N) and spike (S) proteins as well as the receptor binding domain (RBD)^{5,6}
77 of the S protein were measured by ELISA. Antibody responses against the internal N protein
78 have been shown to be elevated in deceased individuals but whether these antibodies
79 contribute to disease severity is unknown^{7,8}. In contrast, responses against the viral surface
80 protein S and, in particular, against the RBD result in virus neutralization⁹. Responses against
81 the RBD are thus likely necessary for protection from re-infection or prevention of
82 symptomatic disease.

83

84 In line with previous reports^{7,8,10-12}, IgG and IgA responses against N, S and RBD were robust
85 in acute disease in the majority of individuals with moderate to severe disease while they
86 were substantially lower in individuals with mild disease (Figure 1b). However, in our cohort,
87 this might also partially be due to earlier study inclusion of patients with mild symptoms
88 (median days from onset of symptoms 11 as compared with 13 and 21.5 in the moderate
89 and severe groups respectively, and 13 in the fatal group) (Supplementary table 1). In fact,
90 while IgG levels remained high in the patients with moderate to severe disease in the
91 convalescent phase, levels had increased in the individuals with mild disease. In contrast, IgA
92 levels from the acute phase, against all antigens, waned substantially during convalescence
93 in most patients (Figure 1b and supplementary fig. 1a). While the levels of IgG against the
94 RBD (Figure 1c), as well as against N and S (Supplementary fig. 1b), exhibited a positive

95 correlation with days from onset of symptoms during the acute phase, this was less
96 pronounced for IgA levels. Altogether, these data confirm that the generation of IgA likely
97 precede that of IgG. Earlier reports of individuals with asymptomatic infection or mild
98 disease also showed robust early IgA responses¹³⁻¹⁵.

99
100 Comparably to another study¹⁶, the levels of both IgG and IgA against all antigens tested,
101 during both acute disease and convalescence, correlated directly with disease severity
102 (Supplementary fig. 2a), indicating that individuals with severe disease or even fatal
103 outcome mounted the highest antibody responses against SARS-CoV-2 antigens. In our
104 cohort, this is further supported by the fact that the patients with moderate/severe disease
105 and fatal outcome for whom we initially observed low IgG titers against RBD, had an early
106 study inclusion (on average 13 days from onset of symptoms); but showed significantly
107 higher titers later during the acute phase (on average 19 days) (Figure 1d-e). Similar kinetics
108 of anti-RBD responses have previously been noted in different patient cohorts¹⁷⁻¹⁹.

109
110 In line with previous reports, the Charlson Comorbidity Index (CCI) and the Body Mass Index
111 (BMI) were associated with disease severity¹ in the cohort (Supplementary fig. 3). However,
112 the presence of comorbidities did not impact the ability to generate antibodies against any
113 of the antigens analyzed (Supplementary fig. 2b).

114
115 As the respiratory tract is the initial site of viral infection and replication, we next measured
116 the levels of IgG and IgA in the upper and lower airways and compared with levels in plasma
117 at matched time points. Due to limited sample volumes, we focused our analyses on IgG and
118 IgA responses against the RBD since these responses are likely most critical for virus
119 neutralization. We found that RBD-specific antibodies could be readily detected in NSW and
120 NPA during the acute phase in several patients across all disease severities (Figure 2a-b and
121 supplementary fig. 4a). In agreement with our observations in plasma, antibody levels in the
122 upper respiratory tract were higher in patients with moderate or severe disease as
123 compared with individuals with mild disease (Figure 2a-b). Both IgG and IgA levels declined
124 significantly in the convalescent phase, with IgG declining to almost undetectable levels
125 (Figure 2a-b). This demonstrates that airway antibody levels wane much faster than those in
126 plasma during convalescence. Low but detectable levels of antibodies to SARS-CoV-2 have
127 previously been reported also in saliva during convalescence²⁰. However, whether these low
128 antibody levels at mucosal sites will be sufficient for protection is not known. We found that
129 RBD-specific IgG and IgA levels in the respiratory tract correlated well with those in plasma
130 during the acute phase but to a lesser extent during convalescence (Supplementary fig. 4b
131 and supplementary fig. 5). When comparing matched NSW, NPA and ETA collected at the
132 same time point during acute disease from intubated patients, significantly higher levels of
133 IgA against the RBD were found in NPA as compared with NSW and ETA (Figure 2c). While
134 this could be partially influenced by differences in sampling method and sample volume,
135 these data suggest that antibody abundance and possibly virus neutralization via IgA differs
136 along the respiratory tract and may be more pronounced in the nasopharynx compared to
137 the lower airways. Hence, nasopharynx antibodies (both IgG and IgA) showed a strong
138 correlation with plasma antibody responses (Supplementary fig. 4b and supplementary fig.
139 5). We also assessed the presence of B cells in the respiratory tract of COVID-19 patients by
140 analyzing the lymphocytes that could be retrieved from NPA and ETA as compared with NPA
141 from three healthy controls (HC). Lymphocyte frequencies were lower in both NPA and ETA

142 from several COVID-19 patients as compared with NPA from HC. However, the relative
143 proportion of B cells was not different. In addition, we observed that in the COVID-19
144 patients, the frequencies of B cells were higher in NPA as compared with ETA which possibly
145 contributes to the higher antibody levels at this site (Supplementary fig. 6).

146
147 Altogether, the data presented so far confirm that moderate and severe COVID-19 result in
148 high levels of circulating antibodies and show that despite IgG being well-maintained during
149 convalescence, antibody levels in the airways decline significantly after the acute phase.
150 Generally, antibodies present in circulation and at local sites are the result of secretion from
151 short-lived plasmablasts and/or terminally differentiated plasma cells in the bone marrow or
152 mucosal sites²¹. The response to a secondary infection once antibody titers have waned
153 below protective levels mostly relies on the presence of resting antigen-specific memory B
154 cells that are rapidly activated upon antigen re-exposure²¹. We therefore investigated the
155 induction and maintenance of antigen-specific memory B cells similar to other studies²²⁻²⁴.
156 We focused on the direct comparison between individuals with mild disease and patients
157 with moderate/severe disease, along with individuals who had reported mild influenza-like
158 symptoms but were SARS-CoV-2 PCR-. Patients with moderate/severe disease who had high
159 circulating IgG and IgA levels were specifically selected for the analysis to be able to compare
160 the opposite ends of the COVID-19 disease spectrum. Matched PBMC from acute disease
161 and convalescence were analyzed side-by-side using fluorescently labelled S and RBD probes
162 to detect antigen-specific B cells²²⁻²⁴. Patients with moderate/severe disease had switched
163 memory B cells specific to S in the acute phase and the memory B cell pool had further
164 expanded in the convalescent phase (ranging from 0.009 to 1.35%; mean 0.42% during
165 convalescence) (Figure 2d-e). Individuals with mild disease showed lower memory B cells
166 during acute disease than the patients with moderate/severe disease, but the levels had
167 increased by the time of convalescent sampling (ranging from 0.17% to 0.64%; mean 0.35%
168 during convalescence) and were comparable between the groups (Figure 2d-e and
169 supplementary fig. 6). Further phenotyping of the S-specific memory B cells indicated that
170 the majority of these cells may be specific for epitopes on S outside of the RBD (Figure 2f).
171 However, it is possible that binding of B cells to RBD could be underestimated as RBD is also
172 present in the S protein. S-specific memory B cells in the circulation were predominantly
173 IgG+, rather than IgA+ (Figure 2f). Low frequencies of S and RBD-specific memory B cells
174 were observed in the PCR- individuals (Figure 2e). However, these were not significantly
175 different from the levels observed in PPHC (Supplementary fig. 7). Collectively, since the
176 majority of individuals infected with SARS-CoV-2 are either asymptomatic or experience only
177 mild COVID-19 symptoms², the possibility of generating antigen-specific memory B cells
178 without experiencing severe disease, would be very important in the prospect of
179 establishing potential immunity at the population level.

180
181 In summary, here we show that COVID-19 disease severity not only determines the
182 magnitude of systemic but also airway antibody levels with efficient generation of virus-
183 specific memory B cells against SARS-CoV-2 also occurring upon mild disease. While plasma
184 IgG levels were generally well detectable at convalescence in all groups, there was a
185 significant decline in airway antibodies after the clearance of infection. This suggests that
186 antibodies in the airways may not be maintained at levels that prevent local virus entry upon
187 re-exposure. However, our data indicate that the majority of infected individuals have the
188 ability to generate anamnestic responses via the memory B cell pool and thereby may be

189 protected or mitigate disease severity. Whether sufficient number of memory B cells will be
190 maintained long-term and to what extent they will prevent the spread of SARS-CoV-2 at the
191 population level remain to be understood. This is critical knowledge to acquire in the near
192 future to evaluate together with the memory B cell response generated after the
193 introduction of SARS-CoV-2 vaccination. Ultimately, the requirements for establishment of
194 long-term protection and immunity will need to be determined.

195

196

197 **Methods**

198

199 **Study design, patient enrollment and sample collection**

200 One hundred and forty-seven (147) PCR-confirmed SARS-CoV-2 infected patients were
201 enrolled at the Karolinska University Hospital and Haga Outpatient Clinic (Haga Närakut),
202 Stockholm, Sweden during March-May 2020 (acute phase) and during April-September 2020
203 (convalescence). Patients were enrolled at various settings, ranging from primary to
204 intensive care. In order to recruit asymptomatic and mild cases, household contacts of
205 COVID-19 patients were screened with PCR and enrolled if positive. A small subset of these
206 individuals who experienced influenza-like symptoms and were possibly exposed to SARS-
207 Cov-2 but had a negative diagnostic PCR (PCR-) (n=9 of whom 3 were household contacts of
208 confirmed patients, 4 had symptoms including fever and 2 had symptoms but no fever) were
209 sampled in the same way and included as controls alongside with 30 pre-pandemic healthy
210 control samples (PPHC) from 2016-2018.

211

212 Respiratory failure was categorized daily according to the respiratory domain of the
213 Sequential Organ Failure Assessment score (SOFA)³. The modified SOFA score (mSOFA) was
214 calculated when arterial partial pressure of oxygen (PaO₂) was not available. In this case
215 peripheral transcutaneous hemoglobin saturation (SpO₂) was used instead⁴. Estimation of
216 the fraction of inspired oxygen (FiO₂) based on O₂ flow was calculated as per the Swedish
217 Intensive Care register definition²⁵. Patients were categorized based on the peak respiratory
218 SOFA or mSOFA value with the 5-point respiratory SOFA score being extended with
219 additional levels to include and distinguish admitted asymptomatic and non-
220 admitted/admitted mild cases and to include fatal outcome added as a seventh level. Ten
221 (10) patients with fatal outcome had peak disease severity score 6 prior to death and 2
222 patients had scores of 4 and 5. For convenience, the resulting 7-point composite peak
223 disease severity (PDS) was condensed into a broader classification consisting of mild (1-2),
224 moderate (3-4), severe (5-6), and fatal (7). Demographics and additional data were collected
225 from medical records, including clinical history and risk factors such as BMI and co-
226 morbidities. Total burden of comorbidities was assessed using the Charlson co-morbidity
227 index (CCI)²⁶ (Supplementary table 1). Additional clinical information on this patient cohort
228 can also be found in Falck-Jones et al²⁷.

229

230 Blood was collected in EDTA-containing tubes from all patients except those admitted to the
231 intensive care unit (ICU) for whom blood was pooled from heparin-coated blood gas syringes
232 discarded in the last 12 hours. For some ICU patients, additional venous blood was also
233 collected in EDTA tubes. Nostril swabs (NSW) and nasopharyngeal aspirates (NPA) were
234 collected from the majority of the patients whereas endotracheal aspirates (ETA) were only
235 collected from patients with mechanical ventilation intubated in the ICU. Admitted patients

236 were sampled during acute disease at up to four timepoints and ICU patient material was
237 collected up at to ten timepoints. For this study, unless otherwise stated, the measurements
238 referring to acute disease were performed with samples collected at the time of study
239 inclusion and during convalescence when patients returned for a follow-up visit.

240

241 The study was approved by the Swedish Ethical Review Authority, and performed according
242 to the Declaration of Helsinki. Written informed consent was obtained from all patients and
243 controls. For sedated patients, the denoted primary contact was contacted and asked about
244 the presumed will of the patient and to give initial oral and subsequently signed written
245 consent. When applicable retrospective written consent was obtained from patients with
246 non-fatal outcomes.

247

248 **Enzyme-linked immunosorbent assay (ELISA)**

249 The presence of IgG or IgA binding against the SARS-Cov-2 Nucleocapsid (N) and Spike (S)
250 trimer or the Receptor Binding Domain (RBD) monomer⁵ in plasma and airway samples was
251 assessed by enzyme-linked immunosorbent assay (ELISA). Recombinant proteins were
252 received through the global health-vaccine accelerator platforms (GH-VAP) funded by the
253 Bill & Melinda Gates Foundation. Briefly, 96-half well plates were coated with 50ng/well of
254 the respective protein. Plates were incubated with a selected duplicate dilution that did not
255 provide background noise against ovalbumin used as a negative control (data not shown)
256 (i.e. 1:20 for plasma samples, 1:2 for NSW and NPA, and 1:5 for ETA in 5% milk/PBS buffer).
257 Duplicate 7-point serial dilutions were initially performed for measuring plasma IgG against
258 RBD during acute disease and the half maximal effective concentration (EC_{50}) was calculated
259 using GraphPad Prism 9. However, since for several samples with low antibody
260 concentration (mostly from the asymptomatic/mild category) the EC_{50} was below the highest
261 dilution used (of 1:20) and therefore below the limit of detection (Supplementary fig. 8a),
262 the maximal optical density (OD) at 1:20 dilution was used instead for this and for all the
263 other measurements subsequently performed. The relation with maximal OD and EC_{50} was
264 also verified in a subset of patients with high IgG and IgA against S (Supplementary fig. 8b).
265 Detection was performed with mouse and goat anti-human IgG or IgA HRP-conjugated
266 secondary antibodies (clone G18-145 from BD Biosciences and polyclonal from
267 ThermoFisher, respectively) followed by incubation with TMB substrate (BioLegend) which
268 was stopped with a 1M solution of sulfuric acid. Blocking with 5% milk/PBS buffer and
269 washing with 0.1% Tween-20/PBS buffer were performed between each step. Absorbance
270 was read at 450nm and background correction at 550nm using an ELISA reader. Data were
271 reported as maximal absorbance i.e. OD, as stated above, and plotted using GraphPad Prism
272 9. All of the antibody measurements in plasma and respiratory samples from SARS-CoV-2
273 patients were run alongside with samples from two different control groups as described
274 above. Interestingly, low but readily detectable IgA reactivity against S was detected in the
275 pre-pandemic healthy controls and in the PCR- individuals (Supplementary fig. 8b). After
276 having verified the specificity and sensitivity of our ELISA assay for IgA detection with
277 limiting sample dilutions (Supplementary fig. 8c), we hypothesize that this might be due to
278 cross-reactivity on the shared portions of the S protein between SARS-CoV-2 and other
279 common cold coronaviruses. Reports have shown that cross-reactivity between
280 coronaviruses exists^{28,29}.

281

282

283 **Flow cytometry**

284 Staining of cells from airway samples was performed fresh. Briefly, samples were centrifuged
285 at 400 g for 5 min at room temperature and cells were washed with sterile PBS. Mucus was
286 removed using a 70 µm cell strainer and cells were subsequently stained with the
287 appropriate combination of fluorescently labelled monoclonal antibodies as illustrated in
288 Supplementary table 3a. Staining of PBMC was performed on previously cryopreserved
289 samples. The appropriate combination of fluorescently labelled monoclonal antibodies
290 binding to different cell surface markers and with fluorescently labelled S and RBD proteins
291 used as probes for antigen-specific B cells is illustrated in Supplementary table 3b. Probes
292 were prepared from biotinylated proteins using a 4:1 molar ratio (protein:fluorochrome-
293 labelled streptavidin) considering the molecular weight of protein monomers and of the
294 streptavidin only. The probes were prepared using streptavidin conjugated to PE and APC for
295 S and with BV421 for the RBD. The gating strategy for the identification of antigen-specific
296 memory B cells is shown in Figure 2d. Briefly, after identification of lymphocytes in single
297 suspension, live B cells, (i.e. cells not expressing CD3/,CD14/CD16/CD56) were gated. From
298 this gate, B cells were further isolated by expression of CD19 and CD20 and then switched
299 memory B cells were identified as IgD-IgM-. From these, S-specific switched memory B cells
300 were identified by binding to both S protein probes. Further characterization was then
301 carried out by analyzing IgG expression (IgA+ switched memory B cells are assumed to mirror
302 IgD-IgM-IgG- B cells) and fluorescently labelled RBD. Stained cells from airway samples were
303 acquired using a BD LSRFortessa while stained PBMC were acquired using a BD FACSAria
304 Fusion both interfaced with the BD FACSDiva Software. Results were analyzed using BD
305 FlowJo version 10.

306

307 **Statistical analyses**

308 All statistical analyses were performed using GraphPad Prism 9. Spearman correlation was
309 used to assess the interdependence of 2 different non-categorical parameters across
310 individuals whereas Wilcoxon matched-pairs signed rank or Mann–Whitney U tests as
311 appropriate, were used to assess differences or similarities for one single parameter
312 between 2 different groups. Kruskal -Wallis with Dunn’s multiple comparisons test was used
313 when assessing comparison between multiple groups.

314

315

316 **Acknowledgments**

317 We thank the patients and healthy volunteers who have contributed to this study. We would
318 also like to thank medical students and hospital staff for assistance with patient sampling
319 and collection of clinical data, the Biomedicum BSL3 core facility, Karolinska Institutet and
320 Fredrika Hellgren for assistance with English editing. This work was supported by grants from
321 the Swedish Research Council, the Swedish Heart-Lung Foundation, the Bill & Melinda Gates
322 Foundation, the Knut and Alice Wallenberg Foundation through SciLifeLab and Karolinska
323 Institutet.

324

325

326

327 **Author contributions**

328 Experimental study design: A.C., Ka.L. and A.S-S. Clinical concept design: A.S-S., M.B., N.J.,
329 J.A., J.S. and A.F. Acquisition and sample processing: M.Y., S. F-J., S.V., B.Ö., E.Å., L.A., R.F-J.,
330 M.Ö. and F.G. Generation of data: A.C., M.Y., S. F-J., S.V. and P.C.G. Provision of custom
331 reagents: D.P., M.M., L.C., and N.P.K. Analysis and interpretation of data: A.C., Ka.L. and A.S-
332 S. Critical revision of the manuscript: all authors. Statistical analysis: A.C., K.L. and S.O. Ka.L.
333 and A.S-S. contributed equally to the study.

334

335

336 **Competing interests**

337 The authors declare no competing financial interests.

338

339

340 **References**

341

- 342 1. Zaki, N., Alashwal, H. & Ibrahim, S. Association of hypertension, diabetes, stroke,
343 cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and
344 fatality: A systematic review. *Diabetes Metab Syndr* **14**, 1133-1142 (2020).
- 345 2. Moghadas, S.M., *et al.* The implications of silent transmission for the control of
346 COVID-19 outbreaks. *Proc Natl Acad Sci U S A* (2020).
- 347 3. Vincent, J.L., *et al.* The SOFA (Sepsis-related Organ Failure Assessment) score to
348 describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-
349 Related Problems of the European Society of Intensive Care Medicine. *Intensive Care*
350 *Med* **22**, 707-710 (1996).
- 351 4. Grissom, C.K., *et al.* A modified sequential organ failure assessment score for critical
352 care triage. *Disaster Med Public Health Prep* **4**, 277-284 (2010).
- 353 5. Walls, A.C., *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
354 Glycoprotein. *Cell* **181**, 281-292 e286 (2020).
- 355 6. Wrapp, D., *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion
356 conformation. *Science* **367**, 1260-1263 (2020).
- 357 7. Atyeo, C., *et al.* Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.
358 *Immunity* **53**, 524-532 e524 (2020).
- 359 8. Guthmiller, J.J., *et al.* SARS-CoV-2 infection severity is linked to superior humoral
360 immunity against the spike. *bioRxiv* (2020).
- 361 9. Piccoli, L., *et al.* Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2
362 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell*
363 (2020).
- 364 10. Zhao, J., *et al.* Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus
365 Disease 2019. *Clin Infect Dis* **71**, 2027-2034 (2020).
- 366 11. Gudbjartsson, D.F., *et al.* Humoral Immune Response to SARS-CoV-2 in Iceland. *N*
367 *Engl J Med* **383**, 1724-1734 (2020).
- 368 12. Gaebler, C., *et al.* Evolution of Antibody Immunity to SARS-CoV-2. *bioRxiv* (2020).
- 369 13. Cervia, C., *et al.* Systemic and mucosal antibody secretion specific to SARS-CoV-2
370 during mild versus severe COVID-19. *bioRxiv*, 2020.2005.2021.108308 (2020).
- 371 14. Staines, H.M., *et al.* Dynamics of IgG seroconversion and pathophysiology of COVID-
372 19 infections. *medRxiv* (2020).

- 373 15. Sterlin, D., *et al.* IgA dominates the early neutralizing antibody response to SARS-CoV-
374 2. *medRxiv* (2020).
- 375 16. Hansen, C.B., *et al.* SARS-CoV-2 Antibody Responses Are Correlated to Disease
376 Severity in COVID-19 Convalescent Individuals. *J Immunol* (2020).
- 377 17. Rydzynski Moderbacher, C., *et al.* Antigen-Specific Adaptive Immunity to SARS-CoV-2
378 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell* (2020).
- 379 18. Lynch, K.L., *et al.* Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and
380 their relationship to disease severity. *Clin Infect Dis* (2020).
- 381 19. Robbiani, D.F., *et al.* Convergent antibody responses to SARS-CoV-2 in convalescent
382 individuals. *Nature* (2020).
- 383 20. Isho, B., *et al.* Persistence of serum and saliva antibody responses to SARS-CoV-2
384 spike antigens in COVID-19 patients. *Sci Immunol* **5**(2020).
- 385 21. Zielinski, C.E., *et al.* Dissecting the human immunologic memory for pathogens.
386 *Immunol Rev* **240**, 40-51 (2011).
- 387 22. Dan, J.M., *et al.* Immunological memory to SARS-CoV-2 assessed for greater than six
388 months after infection. *bioRxiv*, 2020.2011.2015.383323 (2020).
- 389 23. Rodda, L.B., *et al.* Functional SARS-CoV-2-specific immune memory persists after mild
390 COVID-19. *medRxiv* (2020).
- 391 24. Juno, J.A., *et al.* Humoral and circulating follicular helper T cell responses in
392 recovered patients with COVID-19. *Nat Med* (2020).
- 393 25. Intensivvårdsregistret, S. SIR:s riktlinje för registrering av SOFA. . (2018).
- 394 26. Charlson, M.E., Pompei, P., Ales, K.L. & MacKenzie, C.R. A new method of classifying
395 prognostic comorbidity in longitudinal studies: development and validation. *J Chronic*
396 *Dis* **40**, 373-383 (1987).
- 397 27. Falck-Jones, S., *et al.* Functional myeloid-derived suppressor cells expand in blood but
398 not airways of COVID-19 patients and predict disease severity. *medRxiv* (2020).
- 399 28. Grifoni, A., *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans
400 with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501 e1415
401 (2020).
- 402 29. Song, G., *et al.* Cross-reactive serum and memory B cell responses to spike protein in
403 SARS-CoV-2 and endemic coronavirus infection. *bioRxiv* (2020).
- 404
- 405
- 406

407 **Figure legends**

408

409 **Figure 1. Plasma IgG and IgA responses to N, S and RBD across COVID-19 severity during**
410 **acute disease and convalescence.**

411 **a)** Overview of study cohort and controls, timeline of longitudinal sampling, the anatomical
412 compartments analyzed, and the measurements performed. AS=asymptomatic. **b)** Scatter
413 plots show individual levels of plasma IgG and IgA (from left to right) in SARS-CoV-2 infected
414 individuals with different peak disease severity (PDS). Data in cyan and green refer to mild
415 disease (PDS 1 and 2), yellow and orange refer to moderate disease (PDS 3 and 4), red and
416 cayenne refer to severe disease (PDS 5 and 6) and grey refers to patients with fatal outcome
417 (PDS 7). Black lines indicate medians and dotted lines indicate the average background level
418 from PPHC. Mann-Whitney U was used to compare the groups. **c)** Spearman correlation for
419 plasma immunoglobulins against the RBD versus days from onset of symptoms during the
420 acute and the convalescent phases are shown. Circles with black lining refer to convalescent
421 samples. **d-e)** Longitudinal measurements of plasma IgG against RBD on a subset of patients
422 with moderate/severe disease and fatal outcome who had low antibody titers at the time of
423 study inclusion. Levels are shown at the time of study inclusion, during the late acute phase
424 and at convalescence, and shown with respect to days from onset of symptoms and as a
425 group comparison. The black lines connect data points from the same individuals. Wilcoxon
426 test was used to compare the groups separately.

427

428 **Figure 2. Airway IgG and IgA responses to RBD and circulating S-specific memory B cells**
429 **across COVID-19 severity during acute disease and convalescence. a)** Scatter plots of the

430 levels of IgG and IgA to RBD in the upper airway. The black lines indicate median values.
431 Mann-Whitney U was used to compare the groups. **b)** Heat map generated by sorting data
432 according to PDS. The heat map also includes data from PPHC and PCR- as a reference
433 (indicated with PDS 0). Missing data and not available/applicable samples are shown in
434 black. **c)** Comparison of the levels of RBD IgG/A in different upper and lower airway
435 compartments. Data on plasma are shown as a reference. The black lines connect data
436 points from the same individuals. Wilcoxon test was used to compare the groups separately.
437 **d)** Representative example with gating strategy of SARS-Cov-2-specific memory B cells from
438 the four different categories analyzed, and example of further characterization on RBD
439 binding and B cell isotype (IgG+ or IgA+ assumed to correspond to IgD-IgM-IgG- B cells). **e)**
440 Scatter plot shows the quantification of S-specific memory B cells in matched acute (filled)
441 and convalescent (filled with black lining) PBMCs in relation to days in the subset of
442 individuals analyzed color-coded according to PDS. **f)** Pie charts showing the cumulative
443 characterization of RBD binding and memory B cell isotypes. The dotted lines on a) and e)
444 indicate the average background level from PPHC. In a) the line overlaps with not detected
445 (ND) for IgG levels.

446

447




Figure 1

